Characterization of the Epidermal Growth Factor Receptor T790M Mutation in Colorectal Cancer

Altunel, Erdem; Aljamal, Abed Alhalim; Mantyh, John B.; Deak, Kristen; Glover, Wayne; McCall, Shannon J.; Datto, Michael B.; Strickler, John H.; Hsu, David S.

doi:10.1200/po.18.00194

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant adverse events were seen. Finally, as previously described, 16-159 PDX was sensitive to irinotecan and resistant to oxaliplatin [14]. Together, these studies indicated that our screening and validation platform enabled rapid analysis of sensitivity and resistance to standard-of-care agents.…”

Section: High-throughput Drug Screening In Vitro and In Vivo Validatisupporting

confidence: 69%

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Metastatic colorectal cancer (CRC) continues to be a major health problem, and current treatments are primarily for disease control and palliation of symptoms. In this study, we developed a precision medicine strategy to discover novel therapeutics for patients with CRC. Methods: Six matched low-passage cell lines and patient-derived xenografts (PDX) were established from CRC patients undergoing resection of their cancer. High-throughput drug screens using a 119 FDA-approved oncology drug library were performed on these cell lines, which were then validated in vivo in matched PDXs. RNA-Seq analysis was then performed to identify predictors of response. Results: Our study revealed marked differences in response to standard-of-care agents across patients and pinpointed druggable pathways to treat CRC. Among these pathways co-targeting of fibroblast growth factor receptor (FGFR), SRC, platelet derived growth factor receptor (PDGFR), or vascular endothelial growth factor receptor (VEGFR) signaling was found to be an effective strategy. Molecular analyses revealed potential predictors of response to these druggable pathways. Conclusions: Our data suggests that the use of matched low-passage cell lines and PDXs is a promising strategy to identify new therapies and pathways to treat metastatic CRC.

show abstract

Section: High-throughput Drug Screening In Vitro and In Vivo Validatisupporting

confidence: 69%

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…While both approaches lead to the inhibition of EGFR autophosphorylation, TKI efficacy is restricted to cancers that carry EGFR mutations in the TK domain (exons 18-21). Still, these mutations are rarely seen in colorectal cancer[ 8 ]. Available TKIs against EGFR TK mutations are approved for non-small cell lung cancer and include first-generation agents gefitinib and erlotinib and second-generation agents afatinib and dacomitinib[ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report

Buzard,

Douglass,

Gustafson

et al. 2023

World J Gastrointest Oncol

View full text Add to dashboard Cite

Minimally invasive surgery is increasingly indicated in the management of malignant disease. Although oesophagectomy is a difficult operation, with a long learning curve, there is actually a shift towards the laparoscopic/thoracoscopic/ robotic approach, due to the advantages of visualization, surgeon comfort (robotic surgery) and the possibility of the whole team to see the operation as well as and the operating surgeon. Although currently there are still many controversial topics, about the surgical treatment of patients with gastro-oesophageal junction (GOJ) adenocarcinoma, such as the type of open or minimally invasive surgical approach, the type of oesophago-gastric resection, the type of lymph node dissection and others, the minimally invasive approach has proven to be a way to reduce postoperative complications of resection, especially by decreasing pulmonary complications. The implementation of new technologies allowed the widening of the range of indications for this type of surgical approach. The short-term and long-term results, as well as the benefits for the patient - reduced surgical trauma, quick and easy recovery - offer this type of surgical treatment the premises for future development. This article reviews the updates and perspectives on the minimally invasive approach for GOJ adenocarcinoma.

show abstract

Characterization of the Epidermal Growth Factor Receptor T790M Mutation in Colorectal Cancer

Cited by 2 publications

References 11 publications

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer

Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report

Contact Info

Product

Resources

About